Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings

We recently published 10 Stocks With Easy 20-40% Gains. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the last week’s best-performing stocks.

Travere Therapeutics soared by 25.3 percent week-on-week as investors took heart from a stellar earnings performance and cues that the company would kick off the last month of the year on a strong note.

Based on its financial statement on Thursday, Travere Therapeutics, Inc. (NASDAQ:TVTX) swung to a net income of $25.7 million in the third quarter of the year from a $54.8 million net loss in the same period last year.

Total revenues expanded by 162 percent to $164.8 million from $62.9 million year-on-year, helped by strong sales from its kidney disease treatment, Filspari.

According to Travere Therapeutics, Inc. (NASDAQ:TVTX), the drug incurred $90.9 million in sales in the US alone, representing a 155 percent growth year-on-year.

“We delivered outstanding commercial performance in the third quarter, reflecting the growing role of FILSPARI as a foundational therapy in IgAN. This success underscores the strength of our commercial execution and the expanding confidence in FILSPARI among physicians and patients,” Travere Therapeutics, Inc. (NASDAQ:TVTX) President and CEO Eric Dube said.

“We continue to be pleased with the progress of our sNDA review in FSGS and are actively preparing for a potential FDA approval early next year. We are also making meaningful progress toward restarting the pivotal HARMONY Study of pegtibatinase and have positioned the company to support long-term growth. We are entering the final months of 2025 in a position of strength as we remain focused on execution and on expanding our impact for people living with rare diseases,” he noted.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.